UCSF School of Medicine

The UCSF School of Medicine strives to advance human health through a fourfold mission of education, research, patient care and public service.

https://www.ucsf.edu/

 

Oncology & Hematology
12:19

UCSF School of Medicine

A Guide for Shared Decision Making in Sickle Cell Disease

FEATURING Marsha Treadwell
  • 13 views
  • October 29, 2024
08:49

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-Deruxtecan Related ILD - A Real-World Experience

FEATURING Kelsey Natsuhara
  • 734 views
  • October 14, 2024
  • 3
26:22

UCSF School of Medicine

Best of ASCO® 2024: Myeloma Highlights and Practice Impacts

FEATURING Ajai Chari
  • 170 views
  • August 7, 2024
  • 2
25:09

UCSF School of Medicine

Integrative Medicine Approaches for Patients With Primary CNS Tumors

FEATURING Nicholas Butowski
  • 133 views
  • August 2, 2024
09:34

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Impact of ctDNA Surveillance on Clinical Care for Patients With Stage I-III BC"

FEATURING Marla Lipsyc-Sharf
  • 298 views
  • July 24, 2024
  • 1
09:40

UCSF School of Medicine

Trastuzumab Deruxtecan Approval for Metastatic HER2+ Bladder Cancer

FEATURING Vadim Koshkin
  • 262 views
  • June 20, 2024
  • 2
36:18

Insights from ESMO Breast 2024 Annual Meeting

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Award Lecture

FEATURING Hope Rugo
  • 1,179 views
  • June 7, 2024
  • 9
10:09

Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Insights: "Pooled Analysis of T-DXd Retreatment After Recovery From Grade 1 ILD”

FEATURING Hope Rugo
  • 649 views
  • May 22, 2024
  • 4
07:29

Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Insights: "CAPItello-291 Trial PFS2 & TFSC Updates - Capivasertib & Fulvestrant for Patients With Aromatase Inhibitor-Resistant HR+/HER2- Advanced BC"

FEATURING Hope Rugo
  • 337 views
  • May 22, 2024
  • 4
11:03

Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Insights: "TROPION-Breast01 Additional Safety Analysis - Dato-DXd vs. Chemo in Pretreated, Inoperable/Metastatic HR+/HER2- BC"

FEATURING Hope Rugo
  • 350 views
  • May 20, 2024
  • 5
30:03

UCSF School of Medicine

Recent Advances in Advanced Urothelial Cancers: Time for a New Standard of Care?

FEATURING Terence Friedlander
  • 330 views
  • January 24, 2024
  • 3
04:18

Insights from 2023 SABCS

SABCS 2023 Insights: "Comparison of NGS Results From the Cerebrospinal Fluid, Peripheral Blood, and Systemic Metastatic Tumor Tissue of Patients With mBC and LMD"

FEATURING Laura Huppert
  • 261 views
  • December 20, 2023
  • 2
05:48

Insights from 2023 SABCS

SABCS 2023 Insights: "Sequential Use of ADCs T-DXd & SG in Patients With HER2-Low mBC"

FEATURING Laura Huppert
  • 212 views
  • December 20, 2023
  • 2
11:05

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Alliance A051301/BMT-CTN 1201 Study - Ibrutinib + Standard Conditioning and as Consolidation After AutoHCT for R/R ABC-DLBCL"

FEATURING Charalambos Andreadis
  • 41 views
  • December 19, 2023
09:46

Insights from 2023 SABCS

SABCS 2023 Insights: "ELEVATE Study Evaluating Elacestrant in Various Combinations in Patients With ER+, HER2- Locally Advanced or mBC"

FEATURING Hope Rugo
  • 142 views
  • December 15, 2023
  • 1
14:15

Insights from 2023 SABCS

SABCS 2023 Insights: "KEYLYNK-009 Study - Pembro + Olaparib vs. Pembro + Chemo After Induction With Pembro + Chemo for Locally Recurrent Inoperable or Metastatic TNBC"

FEATURING Hope Rugo
  • 321 views
  • December 15, 2023
  • 6
08:24

Insights from 2023 SABCS

SABCS 2023 Insights: "PROs From the CAPItello-291 Trial Investigating Capivasertib and Fulvestrant for Patients With Aromatase Inhibitor-Resistant HR+/HER2- Advanced BC"

FEATURING Hope Rugo
  • 606 views
  • December 15, 2023
  • 2
19:22

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: BCMA/GPRC5D/FcRH5 - CARs/BsAbs - How to Choose in R/R MM

FEATURING Ajai Chari
  • 150 views
  • October 18, 2023
22:17

Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Unraveling the Myeloma Proteome"

FEATURING Arun Wiita
  • 25 views
  • October 10, 2023
07:52

ASCO GU 2023 Conference Coverage

Independent Biomarkers Predictive of Outcomes With Enfortumab Vedotin in Patients With Advanced UC: Analysis of the UNITE Study

FEATURING Tanya Jindal
  • 98 views
  • July 21, 2023
13:15

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Biomarkers Predicting Response to 5 IO Arms in the Neoadjuvant I-SPY2 Trial for eBC - Evaluation of Immune Subtyping in the Response Predictive Subtypes"

FEATURING Denise Wolf
  • 104 views
  • June 14, 2023
  • 1
09:18

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Enfortumab Vedotin +/- Pembro in Pts Who Are Cisplatin-Ineligible With Previously Untreated Locally Advanced or mUC - Additional 3-Month Follow-Up on Cohort K Data"

FEATURING Terence Friedlander
  • 235 views
  • June 8, 2023
  • 2
07:49

ESMO Breast Cancer 2023 Congress Coverage

ESMO Breast Cancer 2023 KEYNOTE-355 Trial: Outcomes in TNBC Patients Who Discontinued Chemo Before Pembro and in Patients With Immune-Mediated AEs

FEATURING Hope Rugo
  • 868 views
  • May 25, 2023
  • 7
17:44

ESMO Breast Cancer 2023 Congress Coverage

ESMO Breast Cancer 2023 Phase 3 DESTINY-Breast04 Trial Safety Analysis: T-DXd vs. TPC in HER2-Low Unresectable and/or Metastatic BC

FEATURING Hope Rugo
  • 51 views
  • May 25, 2023
09:05

AACR 2023 Conference Coverage

AACR 2023 on KEYNOTE-966 Phase 3 Study: Pembro in Combination With Gemcitabine & Cisplatin for Advanced Biliary Tract Cancer

FEATURING Katie Kelley
  • 352 views
  • May 10, 2023
  • 4
06:47

UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+ Solid Tumors

FEATURING Hyunseok Kang
  • 2,122 views
  • April 28, 2023
  • 6
03:32

UCSF School of Medicine

Management of Abemaciclib-Related Diarrhea in HR+/HER2- eBC

FEATURING Sarah Donahue
  • 1,145 views
  • March 31, 2023
  • 5
05:39

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Analysis of the UNITE Study: Biomarkers of Response to Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma

FEATURING Tanya Jindal
  • 103 views
  • March 16, 2023
10:28

UCSF School of Medicine

IO vs. Targeted Therapy as Adjuvant Treatment in BRAFm Advanced Melanoma: When and Why

FEATURING Adil Daud
  • 347 views
  • January 18, 2023
08:41

ASH 2022 Conference Coverage

ASH 2022 Long-Term Outcomes of Patients With TDT Followed Up to 8 Years Post-Treatment With Betibeglogene Autotemcel Gene Therapy and Predictors of Successful Treatment Outcomes in Phase 3 Trials

FEATURING Mark Walters
  • 98 views
  • January 5, 2023
11:43

UCSF School of Medicine

CARTITUDE-1: 2 Years Post-LPI Update on the Phase 1b/2 Study of Cilta-Cel, a BCMA-Directed CAR T-Cell Therapy, in Pts With R/R MM

FEATURING Thomas Martin
  • 222 views
  • October 18, 2022
47

UCSF School of Medicine

Lecture Summary - Impact of Primary Tumor Location on OS and PFS in Patients with mCRC: Analysis of CALGB/SWOG 80405

FEATURING Alan Venook
  • 24 views
  • May 13, 2022
15:07

UCSF School of Medicine

Impact of Primary Tumor Location on OS and PFS in Patients with mCRC: Analysis of CALGB/SWOG 80405

FEATURING Alan Venook
  • 302 views
  • May 10, 2022
  • 1
15:00

UCSF School of Medicine

Ongoing Clinical Trials and Future Directions in Advanced Urothelial Carcinoma

FEATURING Vadim Koshkin
  • 65 views
  • November 16, 2021
20:17

UCSF School of Medicine

ESMO 2021 Updates on 1L Pembro + Chemo vs. Placebo + Chemo for mTNBC: Final Results From a KEYNOTE-355

FEATURING Hope Rugo
  • 124 views
  • November 11, 2021
09:20

UCSF School of Medicine

ESMO 2021 Post Hoc Analyses from PALOMA-2 and PALOMA-3: Effect of Palbociclib + Endocrine Therapy on Time to Chemotherapy Across Subgroups of Pts with HR+/HER2- Advanced Breast Cancer

FEATURING Hope Rugo
  • 310 views
  • November 10, 2021
  • 1
05:01

UCSF School of Medicine

ctDNA-Guided Treatment Strategy: How to Apply in Clinical Practice?

FEATURING Alan Venook
  • 437 views
  • September 1, 2021
13:13

UCSF School of Medicine

ASCO 2021 Updates on Lisinopril or Carvedilol in Prevention of Trastuzumab-Induced Cardiotoxicity in HER2+ EBC: Longitudinal Changes of LVEF Below Normal Levels

FEATURING Pamela Munster
  • 577 views
  • July 6, 2021
  • 1
04:37

UCSF School of Medicine

ASCO 2021 Update: Comparing Cilta-Cel in CARTITUDE-1 vs. Real-World Standard of Care for Pts With Triple-Class Exposed R/R Multiple Myeloma

FEATURING Thomas Martin
  • 135 views
  • June 28, 2021
11:08

UCSF School of Medicine

ASCO 2021 Updates on EV-103: Durability Results and Long-Term Outcome of Enfortumab Vedotin + Pembro in 1L la/mUC

FEATURING Terence Friedlander
  • 450 views
  • June 15, 2021
  • 4
15:52

UCSF School of Medicine

ASH 2020 IKEMA Trial Update on Isatuximab in R/R MM: Should We Consider Isa-Kd a New SoC?

FEATURING Thomas Martin
  • 201 views
  • January 19, 2021
  • 1